US2019127738A1PendingUtilityA1
Multiple exon skipping compositions for dmd
Est. expiryOct 24, 2028(~2.3 yrs left)· nominal 20-yr term from priority
A61P 21/04A61P 21/00C12N 2320/30C12N 2310/3513C12N 15/111C12N 2310/3341C12N 2310/3233C12N 2320/33C12N 2310/11C12N 15/113C12N 2310/321C12N 2310/331A61K 48/00
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Provided are antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon skipping, and methods of use thereof to treat muscular dystrophy.
Claims
exact text as granted — not AI-modified1 - 65 . (canceled)
66 . An antisense oligonucleotide of 21 bases comprising a base sequence that is 100% complementary to 21 consecutive bases of exon 53 of the human dystrophin pre-mRNA,
wherein the base sequence comprises 19 consecutive bases of
(SEQ ID NO: 431)
CTGTTGCCTCCGGTTCTGAAGGTGT,
wherein the antisense oligonucleotide is a morpholino oligomer, and
wherein the antisense oligonucleotide induces exon 53 skipping;
or a pharmaceutically acceptable salt thereof.
67 . A pharmaceutical composition comprising an antisense oligonucleotide of 21 bases comprising
a base sequence that is 100% complementary to 21 consecutive bases of exon 53 of the human dystrophin pre-mRNA,
wherein the base sequence comprises 19 consecutive bases of
(SEQ ID NO: 431)
CTGTTGCCTCCGGTTCTGAAGGTGT,
wherein the antisense oligonucleotide is a morpholino oligomer, and
wherein the antisense oligonucleotide induces exon 53 skipping;
or a pharmaceutically acceptable salt thereof; and
a pharmaceutically acceptable carrier.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.